We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Serum Metabolite Range Expanded Through Technology

By LabMedica International staff writers
Posted on 16 Mar 2011
Analytical technology has identified numerous blood metabolites in human serum that doctors can potentially look at to diagnose and treat health problems.

The metabolites that can be detected in human serum along with their respective concentrations and disease association have been revealed using a variety of techniques. More...


Scientists at the University of Alberta, (Edmonton, AB, Canada), have analyzed blood components to ascertain the most definitive human-serum metabolome to date. The data also includes chemicals found in the blood plasma. More than 20 scientists at six different institutions used state of the art technology to validate past research. The team also conducted its own laboratory experiments to break new ground on the content of human blood chemistry.

They used the following methods with mass spectroscopy (MS): gas chromatography (GC-MS); thin layer chromatography (TLC/GC-MS), liquid chromatography (LC-MS), ultrahigh performance liquid chromatography (UPLC-MS/MS), and direct flow injection (DFI -MS/MS) to identify, quantify and validate more than 4,000 plasma and serum metabolites. High-resolution nuclear magnetic resonance (NMR) spectroscopy was also used. The human serum metabolome database, created by the scientists is open access, allowing anyone to log on and find the expanded list of blood chemicals. Doctors can now tap into the collected wisdom of hundreds of blood-research projects done in the past by scientists all over the world

David Wishart, PhD, a lead author of the study, said, "Right now a medical doctor analyzing the blood of an ailing patient looks at something like 10 to 20 chemicals. We have identified 4,229 blood chemicals that doctors can potentially look at to diagnose and treat health problems. This is the most complete chemical characterization of blood ever done. We now know the normal values of all the detectable chemicals in blood. Doctors can use these measurements as a reference point for monitoring a patient's current and even future health." The study was published on February 16, 2011, in the journal Public Library of Science, PLoS One.

Related Links:

University of Alberta
The human serum metabolome database


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Automated Immunoassay Analyzer
SuperFlex™
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.